853MO Setanaxib plus pembrolizumab for the treatment of recurrent or metastatic squamous cell carcinoma of the head & neck: Results of a randomized, double-blind phase II trial
Jérôme Fayette, Gerald A. Thomas, Amaury Daste, M. Rotarski, B. Castelo, Antonio Rullan, A Levine, Richard Philipson, K.J. Harrington
Topics & Concepts
MedicinePembrolizumabHead and neckOncologyDouble blindRandomized controlled trialBasal cellInternal medicineHead and neck squamous-cell carcinomaHead and neck cancerSurgeryCancerPlaceboImmunotherapyPathologyAlternative medicineBrain Metastases and TreatmentRadiopharmaceutical Chemistry and ApplicationsCancer Immunotherapy and Biomarkers